Easom Eric — SEC Form 4 filings
SEC reporting owner CIK 1914503. 7 Form 4 filings on record with FilingPulse; latest filed 2026-03-23.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-03-18 to 2026-03-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 60,000 shares, $60,635 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: purchase of 50,000 shares @ $1.00 ($49,970) in AN2 Therapeutics, Inc., filed 2024-11-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | Chief Executive Officer, Director | 7 | 2 legs · 60,000 sh · $60,635 | — | 13 |
Form 4 filings — Easom Eric
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 249,999 (derivative) · Disposition to issuer (D): 249,999 (derivative) · Grant/award (A): 225,000 (derivative) · Disposition to issuer (D): 225,000 (derivative) · Grant/award (A): 267,650 (derivative) · Disposition to issuer (D): 267,650 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 112,250 @ $0 · Grant/award (A): 224,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 10,000 @ $1.07 | EDGAR |
| 2025-02-28 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 145,250 @ $0 · Grant/award (A): 290,500 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | AN2 Therapeutics, Inc. (ANTX) | Purchase (P): 50,000 @ $1.00 | EDGAR |
| 2024-03-29 | 4/A | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 99,000 @ $0 | EDGAR |
| 2024-03-18 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 99,000 @ $0 · Grant/award (A): 198,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1914503 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →